Published in AIDS Weekly, February 7th, 2005
The three compounds are BL-1030, a small molecule for the treatment of Inflammatory Bowel Disease; BL-1050, a novel HIV therapeutic; and BL-2010, an innovative technology for the treatment of resistant cancer.
The worldwide exclusive license agreements were signed with Rimonyx Pharmaceuticals, Ltd., of Nes Ziona, Israel for the development of BL-1030; Yissum, the technology transfer company of The Hebrew University in Jerusalem for BL-1050, and Ramot at Tel Aviv University, Ltd., the technology transfer company of Tel Aviv...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.